Study: NCT02311582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: -Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: -Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: -Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: -Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided laser ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided laser ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided laser ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection/debulking
Description: * Optional~* Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection/debulking
Description: * Optional~* Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection/debulking
Description: * Optional~* Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection/debulking
Description: * Optional~* Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: * If no surgical resection/debulking~* Phase II patients only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: * If no surgical resection/debulking~* Phase II patients only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: * If no surgical resection/debulking~* Phase II patients only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw for research purposes
Description: * Phase II patients only~* Drawn prior to MLA or biopsy/surgical resection procedure, and immediately prior to each the first dose of MK-3475. Subsequently, research blood will be drawn at doses 2, 4, 6, 9, 18, 36, and at the end of treatment